Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report

Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re‐administration in patients with advanced thymic carcinoma who developed prior lenvatinib treatment resistance (lenvatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Terashima, Yuto, Hakozaki, Taiki, Takeuchi, Susumu, Hosomi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715831/
https://www.ncbi.nlm.nih.gov/pubmed/36251511
http://dx.doi.org/10.1111/1759-7714.14699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715831/
https://www.ncbi.nlm.nih.gov/pubmed/36251511
http://dx.doi.org/10.1111/1759-7714.14699

Ejemplares similares